This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SEP-226330

Sumitomo Dainippon Pharma Co., Ltd.

Drug Names(s): SEP-226330

Description: SEP-226330 is a norepinephrine and dopamine reuptake inhibitor (NDRI).

Deal Structure: SEP-226330 was originally developed by Sepracor.

In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug